Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations

Related articles

1. Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms

   This article has 5 authors:

   1. Tegan M. Rowsell
   2. Garima Pandey
   3. Lucia Mazzacurati
   4. Narmin E. Amin
   5. Gary W. Reuther

2. Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a g BRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1

   This article has 32 authors:

   1. Ezra Y. Rosen
   2. Marie-Claude Mathieu
   3. Gino B. Ferraro
   4. Philippe Mochirian
   5. Claude Godbout
   6. Hugo Poirier
   7. Sara Fournier
   8. Danielle Henry
   9. Hyeyeon Kim
   10. Robert Papp
   11. Shou Yun Yin
   12. Marie-Eve Leclaire
   13. Robert Houle
   14. Parham Nejad
   15. Joseph D. Schonhoft
   16. Karl E. Zahn
   17. W. Cameron Black
   18. Michel Gallant
   19. Insil Kim
   20. Danielle Ulanet
   21. Paul Basciano
   22. Artur Veloso
   23. Victoria Rimkunas
   24. Timothy A. Yap
   25. Robin Guo
   26. Nicholas Mai
   27. Maria Koehler
   28. Michael Zinda
   29. Anne Roulston
   30. Michal Zimmermann
   31. Stephen J. Morris
   32. Agnel Sfeir

3. Next-Generation Imipridones ONC206 and ONC212 Synergize with Lurbinectedin in Killing Pancreatic Ductal Adenocarcinoma Cells

   This article has 5 authors:

   1. Tej Tummala
   2. Audrey Su
   3. Ashley Sanchez Sevilla Uruchurtu
   4. Christopher G. Azzoli
   5. Wafik S. El-Deiry